Abstract:
On November 19, French pharmaceutical giant Sanofi announced that the European Commission has approved the marketing of its new generation rabies vaccine VaxRabeo, which is suitable for people of all ages and can be used for pre-exposure and post-exposure prevention of rabies. This is the first time in the world that this vaccine has received marketing authorization.

VaxRabeo uses Vero cell technology and is designed to reduce the risk of allergic reactions in recipients. Compared with Sanofi's existing rabies vaccine, the new vaccine has a longer shelf life and better thermal stability. It has a shelf life of up to five years and can remain stable for 96 hours in an environment of up to 27 degrees Celsius before formulation.
The EU approval is based on a controlled clinical study of VaxRabeo and Sanofi’s existing rabies vaccines Verorab and Imovax Rabies. The study covers people of all ages and uses pre-exposure and post-exposure vaccination regimens recommended by the World Health Organization. The results showed that VaxRabeo was able to produce protective antibody levels comparable to existing vaccines and demonstrated good immune responses when boosted 12 months after the initial vaccination or 24 to 36 months after the initial vaccination.
Data from the World Health Organization shows that rabies currently exists in about 150 countries around the world. About 59,000 people die from it every year, and about 29 million people receive post-exposure vaccination. Rabies is mainly transmitted through the saliva of infected animals. Once clinical symptoms appear, the mortality rate is almost 100%, but timely vaccination can effectively prevent the disease.
Comments